Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Nonrelapse Mortality?
The role of allogeneic hematopoietic cell transplant (HCT) in the treatment of older patients with hematologic malignancies has rapidly evolved over the past 2 decades. Historically, older patients were not offered HCT despite being both disproportionally affected by hematologic malignancies and having a higher propensity for higher risk/more aggressive disease. In fact, it was estimated as recently as 2011 that only 6% of patients with acute myelogenous leukemia (AML) older than 60 years in the United States underwent stem cell transplantation [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 13, 2020 Category: Hematology Authors: Thomas G. Knight Tags: Commentary Source Type: research

Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Non-Relapse Mortality?
The role of allogeneic hematopoietic cell transplant (HCT) in the treatment of older patients with hematologic malignancies has rapidly evolved over the past two decades. Historically, older patients were not offered HCT despite being both disproportionally affected by hematologic malignancies and having a higher propensity for higher risk/more aggressive disease. In fact, it was estimated as recently as 2011 that only 6% of AML patients older than 60 in the US underwent SCT.1 However, the development of reduced-intensity conditioning and nonmyeloablative regimens in combination with improved infectious and graft-versus-ho...
Source: Biology of Blood and Marrow Transplantation - October 13, 2020 Category: Hematology Authors: Thomas G Knight Tags: Commentary Source Type: research

Prophylactic foscarnet for human herpesvirus 6: effect on hematopoietic engraftment after reduced intensity conditioning umbilical cord blood transplantation
Umbilical cord blood (UCB) is a valuable alternative for allogeneic hematopoietic stem cell transplantation (HCT). However, delayed engraftment, graft failure, and increased risk for opportunistic infections remain major challenges when considering this donor source. Human herpesvirus-6 (HHV-6) reactivation occurs in the majority of UCB recipients.1-3 Thus, UCB recipients are a particularly vulnerable population for HHV-6 viremia and post-transplant complications with severe sequelae such as delayed hematopoietic recovery, graft failure, and limbic encephalitis. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 11, 2020 Category: Hematology Authors: Najla El Jurdi, John Rogosheske, Todd DeFor, Nelli Bejanyan, Mukta Arora, Veronika Bachanova, Brian Betts, Fiona He, Shernan Holtan, Murali Janakiram, Samantha Larson, Joseph Maakaron, Armin Rashidi, Erica Warlick, John E. Wagner, Jo-Anne H Young, Daniel Source Type: research

Specific class I HLA supertypes but not HLA zygosity or expression are associated with outcomes following HLA-matched allogeneic hematopoietic cell transplant: HLA supertypes impact allogeneic HCT outcomes
Eliciting an adaptive immune response against infection or malignancy requires precise interaction of T cell receptors on cytotoxic T lymphocytes with peptides bound to human leukocyte antigen (HLA) expressed on the surface of antigen-presenting cells1, 2. Effective immune surveillance benefits from extensive polymorphism within the HLA genetic region encoding amino acid residues centered in the peptide-binding groove, where diversity expands the overall repertoire of HLA-bound peptide ligands and their respective antigen-specific T cells2. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 11, 2020 Category: Hematology Authors: Christine Camacho-Bydume, Tao Wang, Jennifer A. Sees, Marcelo Fernandez-Vi ña, Muhammad Bilal Abid, Medhat Askar, Amer Beitinjaneh, Valerie Brown, Paul Castillo, Saurabh Chharbra, Shahinaz M. Gadalla, Jing-Mei Hsu, Malek Kamoun, Aleksandr Lazaryan, Taiga Source Type: research

Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis
Cytomegalovirus (CMV) is a common viral infection in recipients of allogeneic hematopoietic cell transplantation (allo HCT).1,2 Untreated CMV infection results in significant morbidity and mortality in this population, necessitating the use of pre-emptive anti-viral therapies in patients with detectable viremia.3,4 CMV-active antiviral agents have significant adverse effects including myelosuppression (ganciclovir and valganciclovir), or renal injury (foscarnet), among others, leading to additive toxicities in allo HCT recipients requiring treatment for CMV. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 10, 2020 Category: Hematology Authors: A. Lin, J. Flynn, L. DeRespiris, B. Figgins, M. Griffin, C. Lau, A. Proli, S.M. Devlin, C. Cho, R. Tamari, A.A. Jakubowski, E.B. Papadopoulos, S.A. Giralt, M.A. Perales, S.K. Seo, B. Shaffer Source Type: research

The Role of Blood and Marrow Transplantation in Treating Pediatric Chronic Myelogenous Leukaemia in the Era of Tyrosine Kinase Inhibitors
The introduction of tyrosine kinase inhibitors (TKIs) in 2001 revolutionised the treatment of CML in adults, largely supplanting blood and marrow transplantation (BMT). Within 5 years these revolutionary drugs had also been approved for use in pediatric patients with CML. However, due to the low disease incidence and subsequent lack of robust clinical trial data in pediatric CML, the management of pediatric CML is largely extrapolated from adult data. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 10, 2020 Category: Hematology Authors: Delphine Veys, Persis Amrolia, Ajay Vora, Paul Veys, Anupama Rao, Michael Gattens Source Type: research

Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease and Search Prognosis
Allogeneic hematopoietic cell transplantation (alloHCT) is potentially curative for hematologic malignancies and non-malignant disorders including inherited metabolic disorders, hemoglobinopathies and bone marrow failure syndromes. The optimal donor for alloHCT is an HLA identical sibling. Unfortunately, approximately 70% of patients in need of alloHCT will not have a fully matched donor in their family and must pursue an unrelated adult donor (URD), umbilical cord blood (UCB) or a mismatched related donor as a graft source. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 9, 2020 Category: Hematology Authors: Jason Dehn, Pintip Chitphakdithai, Bronwen E. Shaw, Abby A. McDonald, Steven M. Devine, Linda J. Burns, Stephen Spellman Source Type: research

Risk factors for haematopoietic stem cell transplant (HSCT) associated bone loss
BONE MARROW TRANSPLANTATION (BMT) also called haematopoietic stem cell transplant (HSCT) is the treatment of choice for many haematological diseases including haematological malignancies and different types of anaemia1. The number of HSCT is increasing every year, mainly because of advanced research that has allowed an expansion in the number of indications for which it has become the first-line therapy2. The long-term survival of patients that have undergone BMT continues to improve with several advances in transplantation techniques and supportive care practices. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 9, 2020 Category: Hematology Authors: Zehva Khan, Nidhi. B. Agarwal, Dinesh Bhurani, Mohd Ashif Khan Source Type: research

Hematopoietic Cell Transplantation: Practice predictions for the Year 2023
The field of hematopoietic cell transplantation (HCT) is characterized by substantial practice variations in therapeutic approaches including preferred donor, graft source, conditioning regimens and graft-versus-host disease (GVHD) prophylaxis. Many factors influence practice but a major one is the lack of definitive data about best practices. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts clinical trials that aim to define best practices and improve the outcomes of patients undergoing HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 9, 2020 Category: Hematology Authors: Nosha Farhadfar, Linda J. Burns, Tatenda Mupfudze, Bronwen E. Shaw, Catherine M. Bollard, Steven M. Devine, Mary M. Horowitz, Richard J. Jones, Hemant S. Murthy, John R. Wingard, Stephanie J. Lee Source Type: research

Impact of a Clostridioides difficile testing computerized clinical decision support on an adult stem cell transplant and hematologic malignancies unit
Clostridioides difficile infection rates in hospitalized hematopoietic stem cell transplant (HSCT) and hematologic malignancy (HM) patients are higher than in the general population. This is related both to extensive exposure to antibiotics as well as to frequent and often prolonged hospitalization. In this population, with numerous potential causes for diarrhea, a subset of C. difficile detection is presumed to represent colonization rather than clinical infection. Use of decision support tools to guide ordering in hospitalized patients has been reported to decrease both C. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 8, 2020 Category: Hematology Authors: Chad D Nix, William B Messer, Molly L Hale, James S. Lewis, Lynne M Strasfeld Source Type: research

Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia
Risk assessment in chronic myelomonocytic leukemia (CMML) is a critical aspect for its management to capture the heterogeneity of this disease.1 In spite of the introduction of several prognostic tools from different groups over the past decade, risk stratification can still be challenging.2 Current collaborative recommendations from the European Hematology Association and the European Leukemia Network suggest to use the CMML-specific scoring system (CPSS) or the MD Anderson prognostic score as such tools if mutational profiling is not available. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 8, 2020 Category: Hematology Authors: Nico Gagelmann, Rashit Bogdanov, Friedrich St ölzel, Christina Rautenberg, Victoria Panagiota, Heiko Becker, Aleksandar Radujkovic, Thomas Luft, Maximilian Christopeit, Jürgen Finke, Uwe Platzbecker, Markus Ditschkowski, Thomas Schroeder, Michael Koldeh Source Type: research

Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia After an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of the Japan Society for Hematopoietic Cell Transplantation
Cytomegalovirus (CMV) infection is a major infectious complication following an allogeneic hematopoietic stem cell transplantation (allo-HSCT). CMV end-organ disease is a significant cause of morbidity and mortality following an allo-HSCT despite advances in the early diagnosis and managements of CMV infection (1-5). Early detection of CMV reactivation through CMV antigenemia or polymerase chain reaction (PCR) assay and the use of preemptive antiviral therapy using ganciclovir (GCV), valganciclovir (VGCV), or foscarnet (FOS) decreased the incidence of CMV end-organ disease within the first 100 days after allo-HSCT to (Sour...
Source: Biology of Blood and Marrow Transplantation - October 8, 2020 Category: Hematology Authors: Katsuto Takenaka, Yasushi Onishi, Takehiko Mori, Tsuneaki Hirakawa, Yuuma Tada, Naoyuki Uchida, Takeshi Kobayashi, Yoshinobu Kanda, Yukiyasu Ozawa, Shuichi Ota, Hiroatsu Iida, Kentaro Fukushima, Takafumi Kimua, Takahiro Fukuda, Yoshiko Atsuta, Keitaro Mat Source Type: research

Limitations of Applying the Hematopoietic Cell Transplantation Comorbidity Index in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation
Allogeneic HCT (alloHCT) is a curative treatment option for many children with malignant and non-malignant diseases [1 –9]. However, alloHCT is associated with the risk of significant toxicities that can result in substantial morbidity and mortality. Identifying which patients are at high risk for transplant related mortality, prior to alloHCT, is crucial both to guide decision-making with patients and families an d to inform the alloHCT approach. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 7, 2020 Category: Hematology Authors: Larisa Broglie, Jenny Ruiz, Zhezhen Jin, Justine M. Kahn, Monica Bhatia, Diane George, James Garvin, Prakash Satwani Source Type: research

Matched Family Donor Lymphocyte Infusions as First Cellular Therapy for Patients with Severe Primary T-cell Deficiencies
Primary immunodeficiencies are a heterogeneous group of rare inborn diseases affecting different components of the immune system. [1] A subgroup of patients with severe primary T-cell deficiencies is at risk for life-threatening viral and opportunistic infections. Without the reconstitution of a functional T-cell system, the prognosis is often dismal and infections lead to death within the first years of life. The establishment of T-cell function is usually achieved by allogeneic hematopoietic stem cell transplantation (HSCT), which can be preceded by conditioning regimens of various intensity. (Source: Biology of Blood an...
Source: Biology of Blood and Marrow Transplantation - October 2, 2020 Category: Hematology Authors: Manfred Hoenig, Joachim Roesler, Markus G. Seidel, Michael H. Albert, Fabian Hauck, Britta Maecker-Kolhoff, Britta Eiz-Vesper, Katharina Kleinschmidt, Klaus-Michael Debatin, Eva-Maria Jacobsen, Ingrid Furlan, Meinolf Suttorp, Catharina Schuetz, Ansgar S. Tags: Brief Article Source Type: research

UM171-expanded cord blood transplants support robust T cell reconstitution with low rates of severe infections
Use of cord blood (CB) as a stem cell source extends the curative potential of hematopoietic stem cell (HSC) transplantation (HSCT) for patients with hematologic malignancies for whom HLA-matched sibling and unrelated donors (MUD) are unavailable [1]. Although the overall survival results for CB transplantation are generally comparable to the results obtained with HLA-matched transplants owing to lower incidence of chronic GVHD and relapse, CB transplants have a higher rate of delayed engraftment and transplant-related mortality (TRM). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 2, 2020 Category: Hematology Authors: Maude Dumont-Lagac é, Qi Li, Mégane Tanguay, Jalila Chagraoui, Tibila Kientega, Guillaume B. Cardin, Ann Brasey, Assya Trofimov, Cédric Carli, Imran Ahmad, Nadia M. Bambace, Léa Bernard, Thomas L. Kiss, Jean Roy, Denis-Claude Roy, Sébastien Lemieux, Source Type: research

Cellular Immunotherapies in Pre-Clinical Large Animal Models of Transplantation
Acute and chronic rejection as well as the deleterious effects associated with long-term immunosuppression are leading causes of allograft failure following transplantation. The use of “regulatory” cell therapy to prevent graft-versus-host disease (GVHD) and improve solid organ transplant outcomes has been a long-standing endeavor. While numerous murine studies have documented the effects of various “regulatory” cell types in modulating the alloimmune response in favor of graft tolerance, translation to pre-clinical and clinical models has been met with mixed results. (Source: Biology of Blood and M...
Source: Biology of Blood and Marrow Transplantation - October 1, 2020 Category: Hematology Authors: Abraham J. Matar, Rebecca L. Crepeau, Raimon Duran-Struuck Source Type: research

Acute Graft-versus-Host-Disease other than typical targets: between myths and facts
Acute Graft-versus-Host-Disease (aGVHD) remains a major contributor to transplantation related deaths and the most significant barrier to the success of allogeneic hematopoietic stem cell transplantation (allo-HSCT)1,2. Despite prophylactic treatments with immunosuppressive agents, approximately 30-50% of transplantation recipients develop aGVHD targeting the well-recognized organs represented by skin, liver and gastrointestinal tract (GI). Identification of these target organs resulted in the classification of aGVHD proposed by Glucksberg3, subsequently modified by Przepiorka4 and the Mount Sinai aGVHD  (MAGIC) Inter...
Source: Biology of Blood and Marrow Transplantation - October 1, 2020 Category: Hematology Authors: Jacopo Mariotti, Olaf Penack, Luca Castagna Source Type: research

Clinical Outcomes in Patients With FLT3-ITD –Mutated Relapsed/Refractory Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplant After Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Patients with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) relapsed or refractory (R/R) acute myeloid leukemia (AML) have a dismal prognosis and limited effective treatment options outside of clinical trials [1-3]. In patients with R/R AML, performing a hematopoietic stem cell transplant (HSCT) after first salvage therapy decreases the risk of relapse and improves relapse-free survival (RFS) and overall survival (OS) probabilities [4]. Traditional cytotoxic salvage chemotherapy has been largely ineffective in controlling FLT3-ITD R/R disease, enabling ≤ 20% of patients to proceed to HSCT [5,6]....
Source: Biology of Blood and Marrow Transplantation - October 1, 2020 Category: Hematology Authors: Siddhartha Ganguly, Jorge E. Cortes, Alwin Kr ämer, Mark J. Levis, Giovanni Martinelli, Alexander E. Perl, Nigel H. Russell, Meena Arunachalam, Cedric Dos Santos, Guy Gammon, Arnaud Lesegretain, Derek E. Mires, Hoang Pham, Yibin Wang, Samer K. Khaled Source Type: research

Statistical Methods for Time-Dependent Variables in Hematopoietic Cell Transplantation Studies
A time-dependent variable occurs in hematopoietic cell transplantation (HCT) studies when a value of a variable changes over time. For example, the patient's infection status after HCT is a time-dependent variable. At any time post-HCT, a patient's current infection status at time t has 2 values, infected or not infected, or rather, no infection before time t and infection before time t. These infections are often a cause of death, and after getting infections, patients often show worse outcomes compared to before getting infections [1,2]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 1, 2020 Category: Hematology Authors: Soyoung Kim, Brent Logan, Marcie Riches, Min Chen, Kwang Woo Ahn Source Type: research

Tatistical methods for time-dependent variables in hematopoietic cell transplantation studies
A time-dependent variable occurs in hematopoietic cell transplantation (HCT) studies when a value of a variable changes over time. For example, the patient's infection status after HCT is a time-dependent variable. At any time post HCT, a patient's current infection status at time t has two values, infected or not infected, or rather, no infection before time t and infection before time t. These infections are often a cause of death and after getting infections patients often show worse outcomes compared to before getting infections (Ustun et al, 2018; Abidi et al., 2019). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 30, 2020 Category: Hematology Authors: Soyoung Kim, Brent Logan, Marcie Riches, Min Chen, Kwang Woo Ahn Source Type: research

Acute Respiratory Failure Outcomes in Patients with Hematologic Malignancies and Hematopoietic Cell Transplant: A Secondary Analysis of the EFRAIM Study
Historically patients with hematologic malignancies (HM) and hematopoietic cell transplant (HCT) who developed critical illness were considered to be at very high risk of dying in the intensive care unit (ICU)1, leading to subsequent guidelines recommending refusal or limitation of ICU care for this population2. With advances in critical care, oncology and infectious disease practices, mortality rates in this population have improved from 80-95% to rates that mirror the general ICU population across certain conditions3,4. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 30, 2020 Category: Hematology Authors: Laveena Munshi, Michael Darmon, Marcio Soares, Peter Pickkers, Philippe Bauer, Anne-Pascale Meert, Ignacio Martin Loeches, Thomas Staudinger, Frederic Pene, Massimo Antonelli, Andreas Barratt-Due, Alexandre Demoule, Victoria Metaxa, Virginie Lemiale, Fabi Source Type: research

Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for most adults with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Since HCT using conventional myeloablative conditioning (MAC) can be associated with higher toxicity and mortality rates, reduced intensity conditioning (RIC) regimens have been increasingly used in the past two decades for HCT in older and less fit patients with AML or MDS.1,2 A recent prospective randomized Blood and Marrow Transplant Clinical Trials Network (BMT CTN)  0901 trial demonstrated significantly improved disease-free survival (DFS) benefit ...
Source: Biology of Blood and Marrow Transplantation - September 29, 2020 Category: Hematology Authors: Nelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, Claudio Brunstein, Hailin Wang, Erica D. Warlick, Sergio Giralt, Taiga Nishihori, Rodrigo Martino, Jakob Passweg, Ajoy Dias, Edward Copelan, Gregory Hale, Robert Peter Gale, Melhem Solh, Mohamed A. Kharfan-D Source Type: research

Long-Term Follow-up of High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Children and Young Adults with Metastatic or Relapsed Ewing Sarcoma: A Single-Institution Experience
Ewing sarcoma (EWS) arises in bone and soft tissue and most commonly occurs in adolescents and young adults. With current therapy, the survival rate ranges from 75% to 80% for patients with localized disease at diagnosis [1,2]. Unfortunately, patients with metastatic disease at diagnosis have a much poorer outcome when treated with standard chemotherapy with a 3-year survival rate range between 10% and 30% [1-3]. Further, the survival rate for patients with recurrent disease also remains poor despite aggressive treatment; 5-year overall survival (OS) for patients with recurrent or progressive disease after first-line thera...
Source: Biology of Blood and Marrow Transplantation - September 29, 2020 Category: Hematology Authors: Anna B. Pawlowska, Victoria Sun, George T. Calvert, Nicole A. Karras, Judith K. Sato, Clarke P. Anderson, Jerry C. Cheng, Julie F. DiMundo, Joseph D. Femino, J'Rick Lu, Dongyun Yang, Andrew Dagis, James S. Miser, Joseph Rosenthal Source Type: research

Clinical benefits of pre-conditioning intervention in patients with relapsed or refractory acute myeloid leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter analysis
The outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML) not in complete remission remain unsatisfactory. Numerous previous studies have evaluated the impact of various disease, patient, and transplant factors on the outcomes of allogeneic HCT in non-remission AML [1 –21]. Several studies, including our previous study, constructed scoring systems to determine patients who are likely or unlikely to benefit from HCT [3, 8, 21]. In those studies, the disease burden just prior to allogeneic HCT was consistently identified as a significant factor negatively affecti ...
Source: Biology of Blood and Marrow Transplantation - September 28, 2020 Category: Hematology Authors: Takayoshi Tachibana, Junya Kanda, Takuma Ishizaki, Yuho Najima, Masatsugu Tanaka, Noriko Doki, Shin-ichiro Fujiwara, Shun-ichi Kimura, Makoto Onizuka, Satoshi Takahashi, Takeshi Saito, Takehiko Mori, Shin Fujisawa, Emiko Sakaida, Takuya Miyazaki, Nobuyuki Tags: ORIGINAL ARTICLE Source Type: research

Long term follow-up of high dose chemotherapy with autologous stem cell transplantation in children and young adults with metastatic or relapsed Ewing's sarcoma – a single-institution experience
Ewing Sarcoma (EWS) arises in bone and soft tissue and most commonly occurs in adolescents and young adults. With current therapy, the survival rate ranges from 75 –80% for pts with localized disease at diagnosis.1, 2 Unfortunately, pts with metastatic disease at diagnosis have a much poorer outcome when treated with standard chemotherapy with a 3-year survival rate range between 10-30%.1-3 Further, the survival rate for pts with recurrent disease also remai ns poor despite aggressive treatment; 5-year OS for pts with recurrent or progressive disease after first-line therapy ranges between 0 to 20%. (Source: Biology ...
Source: Biology of Blood and Marrow Transplantation - September 28, 2020 Category: Hematology Authors: Anna B. Pawlowska, Victoria Sun, George T. Calvert, Nicole A. Karras, Judith K. Sato, Clarke P. Anderson, Jerry C. Cheng, Julie F. DiMundo, Joseph D. Femino, J'Rick Lu, Dongyun Yang, Andrew Dagis, James S. Miser, Joseph Rosenthal Source Type: research

NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations
A lymphocyte of the innate immune response, Natural Killer (NK) cells are phenotypically defined by the absence of CD3 and the presence of CD56 on their surface.1, 2 Functionally, they resemble CD8+ cytotoxic T cells.3 NK cells derive their name from their ability to spontaneously kill their targets without the need for a prior encounter of the antigen, as they have readily available lytic granules that can activate within minutes,4 unlike their T cell counterparts. NK cell targets include stressed, virally-infected, and transformed cells. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 27, 2020 Category: Hematology Authors: Carlos E. Sanchez, Ehsan P. Dowlati, Ashley E. Geiger, Kajal Chaudhry, Matthew A. Tovar, Catherine M. Bollard, Conrad Russell Y. Cruz Source Type: research

Sexual functioning in long-term survivors of hematopoietic cell transplantation
Patients who undergo hematopoietic cell transplantation (HCT) may experience a decline in sexual health as one of their many survivorship issues.1-4 Sexual health can be divided into being ‘sexually active’ and ‘sexual function’, which refers to qualities of sexual well-being including sexual problems.5 Sexual issues after HCT are common with survivors reporting an inability to have sex (36%), derive pleasure from sex (31%), or have interest in sex (28%).6 Sexual dysfunction i s associated with patients’ medical status as well as their perceived health status and psychosocial profile. (Source:...
Source: Biology of Blood and Marrow Transplantation - September 27, 2020 Category: Hematology Authors: Karen L. Syrjala, Helene Schoemans, Jean C. Yi, Shelby L. Langer, Ahona Mukherjee, Lynn Onstad, Stephanie J. Lee Source Type: research

Comorbidities Predict Inferior Survival in Patients receiving Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma: A Multicenter Analysis
Chimeric Antigen Receptor (CAR) T-cell therapy is approved for treatment of relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Here, we evaluate whether comorbidities, calculated by the Cumulative Illness Rating Scale (CIRS), predict survival for these patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 27, 2020 Category: Hematology Authors: Adam S. Kittai, Ying Huang, Max Gordon, Nathan Denlinger, Agrima Mian, Lindsey Fitzgerald, Jennifer Bishop, Sarah Nagle, Deborah M. Stephens, Samantha JaglowskiMPH, Brian Hill, Alexey V. Danilov Source Type: research

K Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations
A lymphocyte of the innate immune response, Natural Killer (NK) cells are phenotypically defined by the absence of CD3 and the presence of CD56 on their surface.1, 2 Functionally, they resemble CD8+ cytotoxic T cells.3 NK cells derive their name from their ability to spontaneously kill their targets without the need for a prior encounter of the antigen, as they have readily available lytic granules that can activate within minutes,4 unlike their T cell counterparts. NK cell targets include stressed, virally-infected, and transformed cells. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 27, 2020 Category: Hematology Authors: Carlos E. Sanchez, Ehsan P. Dowlati, Ashley E. Geiger, Kajal Chaudhry, Matthew A. Tovar, Catherine M. Bollard, Conrad Russell Y. Cruz Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 25, 2020 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 25, 2020 Category: Hematology Source Type: research

Officers and Directors of ASTCT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 25, 2020 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 25, 2020 Category: Hematology Source Type: research

ASTCT Notes
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 25, 2020 Category: Hematology Source Type: research

Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant
Donor lymphocyte infusions (DLIs) are a major therapeutic approach for relapse and conversion of mixed chimerism (MC) after allogeneic hematopoietic cell transplant (AlloHCT) (1,2). The effectiveness and toxicity of DLI has been a matter of study, and several variables have been identified. Of these, the total number of CD3+ cells infused per recipient's weight has been identified as key for the development of graft-versus-host disease (GvHD), a major drawback after DLI (3). In this context, an approach using a CD3+ dose-escalation schedule was ideated in order to minimize GvHD while attempting to retain the graft-versus-t...
Source: Biology of Blood and Marrow Transplantation - September 24, 2020 Category: Hematology Authors: Guillermo Ort í, Carles Palacio-Garcia, Irene García-Cadenas, Isabel Sanchez-Ortega, María José Jimenez, Carmen Azqueta, Guillermo Villacampa, Christelle Ferrà, Rocio Parody, Rodrigo Martino, Francesc Bosch, Sergi Querol, David Valcárcel Source Type: research

Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma
Autologous hematopoietic cell transplantation (AHCT) is a standard of care for many high-risk lymphomas, including mantle cell lymphoma [1], relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHL) [2,3], T-cell NHL (T-NHL) [4], and classical Hodgkin lymphoma (HL) [5]. Unfortunately, less than half of these patients experience sustained remissions following AHCT. Patients with adverse pretransplantation risk factors, including early failure of upfront therapy [6] and persistent disease on functional imaging [7,8] have even worse outcomes. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 23, 2020 Category: Hematology Authors: Sherilyn A. Tuazon, Ryan D. Cassaday, Theodore A. Gooley, Brenda M. Sandmaier, Leona A. Holmberg, Stephen D. Smith, David G. Maloney, Brian G. Till, Daniel B. Martin, Victor A. Chow, Joseph G. Rajendran, Darrell R. Fisher, Manuela C. Matesan, Sally J. Lun Source Type: research

Evaluation of disease risk comorbidity index after allogeneic stem cell transplantation in a cohort with patients transplanted with in-vitro partially T-cell depleted grafts.
Allogeneic stem cell transplantation (HSCT) is the only curative treatment for most haematological malignancies. Outcomes of HSCT mainly depend on disease characteristics and patient conditions. Tools that help physicians to predict outcomes are important to determine which patient would most likely benefit of HSCT. Over the last decades, several prognostic scores have been developed. The Disease Risk Index (DRI)1, 2, that include type and status of disease at transplant time is predictive of overall survival (OS), but does not integrate patient's comorbidities and overall conditions. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 23, 2020 Category: Hematology Authors: Yan Beauverd, Sarah Morin, Mitja Nabergoj, Caroline Stephan, Carmen De Ramon Ortiz, Anne-Claire Mamez, Elif Mahne, Anna Petropoulou, Federica Giannotti, Christian Ayer, Benjamin Bruno, Laura Bounaix, Maria Anastasiou, Maria Mappoura, Thien-An Tran, Stavro Source Type: research

Evaluation of next-generation sequencing and Crystal Digital PCR ™ for chimerism monitoring of post-allogeneic haematopoietic stem cell transplantation.
Haematopoietic stem cell transplantation (HSCT) is a curative treatment for most haematological diseases. To evaluate the level of donor engraftment, chimerism must be carefully monitored after HSCT. Chimerism monitoring is very important in the engraftment phase to detect graft failure but also post-HSCT to detect the risk of disease relapse in malignant disease1,2. Currently, two historical methods, short tandem repeat (STR) PCR and qPCR (quantitative PCR) methods, are routinely performed in laboratories. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 23, 2020 Category: Hematology Authors: Pascal Pedini, Nicem Cherouat, Agnes Basire, Sophie Simon, Laur ène Budon, Monique Pourtein, Sandra Grondin, Philippe Moskovtchenko, Jacques Chiaroni, Gérard Michel, Coralie Frassati, Christophe Picard Source Type: research

Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis
Chimeric antigen receptor CD-19 T cell (CAR-T) therapy is approved in the United States for the treatment of acute lymphocytic leukemia (ALL) [1] and aggressive B cell lymphomas [2-4]. Although clinically effective, these agents are associated with substantial morbidity and mortality due to adverse events [5-7]. The most common side effect is cytokine release syndrome (CRS) [8], which is a phenomenon noted within the first 2 weeks of therapy of CAR-T infusion, resulting in a systemic inflammatory response syndrome with fevers, hypotension, and/or hypoxia [9]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2020 Category: Hematology Authors: Avirup Guha, Daniel Addison, Prantesh Jain, Jahir M. Gutierrez, Arjun Ghosh, Claire Roddie, Marcos de Lima, Sadeer Al-Kindi, Guilherme H. Oliveira Source Type: research

Loss of FGFR3 accelerates bone marrow suppression-induced hematopoietic stem and progenitor cell expansion by activating FGFR1-ELK1-Cyclin D1 signaling
The chemotherapy or radiation therapy has been a major treatment for many types of diseases, especially malignant tumors 1. However, the two therapeutic ways often result in many side effects, especially bone marrow (BM) suppression 2, 3. Patients with BM suppression generate anemia and low immunity to aggravate the disease 3, 4. Leukemia patients that frequently had cytopenia or the dysfunction of normal blood cells produce higher mortality and morbidity 5-7. Therefore, it is urgent to strengthen hematopoietic regeneration in the process of therapy-induced BM suppression. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2020 Category: Hematology Authors: Qiuju Ran, Chen Guo, Chun Sun, Qing Liu, Haiting He, Wenjie Zhao, Jizhou Zhang, Yechen Xiao Source Type: research

Cardiovascular Events Associated with Chimeric Antigen Receptor T (CAR-T) Therapy: Cross-Sectional FAERS Analysis
Chimeric antigen receptor CD-19 T cell (CAR-T) therapy is approved in the United States (US) for the treatment of acute lymphocytic leukemia (ALL)1 and aggressive B-cell lymphomas2-4. Although clinically effective, these agents are associated with substantial morbidity and mortality due to adverse events5-7. The most common side effect is cytokine release syndrome (CRS)8, which is a phenomenon noted within the first two weeks of therapy of CAR-T infusion resulting in a systemic inflammatory response syndrome with fevers, hypotension, and/or hypoxia9. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2020 Category: Hematology Authors: Avirup Guha, Daniel Addison, Prantesh Jain, Jahir M. Gutierrez, Arjun Ghosh, Claire Roddie, Marcos de Lima, Sadeer Al-Kindi, Guilherme H. Oliveira Source Type: research

Matched versus Haploidentical Hematopoietic Stem Cell Transplantation as Treatment Options for Primary Immunodeficiencies in Children
Primary immunodeficiencies (PIDs) encompass a heterogeneous group of diseases affecting all components of the immune system 1. They are caused by mutations in various genes and may phenotypically present with infections, as well as with autoimmune phenomena and malignancies 2. Despite advances in gene therapy, allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for most children with various malignant or nonmalignant diseases, including selected PIDs. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 19, 2020 Category: Hematology Authors: Ursula Holzer, Michaela D öring, Thomas Eichholz, Martin Ebinger, Manon Queudeville, Dominik Turkiewicz, Klaus Schwarz, Rupert Handgretinger, Peter Lang, Jacek Toporski Source Type: research

Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic Syndromes
The myelodysplastic syndromes (MDS) are a heterogeneous collection of clonal hematopoietic malignancies characterized by poor overall survival owing to ineffective hematopoiesis, progressive cytopenias, and transformation to acute myelogenous leukemia [1]. Current therapeutics for MDS are based primarily on stratification into lower-risk and higher-risk disease using clinical prognostic scoring systems [2,3]. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy for MDS. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 18, 2020 Category: Hematology Authors: Tania Jain, Amy E. DeZern Tags: Commentary Source Type: research

Outcome After Cord Blood Transplantation Using Busulfan Pharmacokinetics-Targeted Myeloablative Conditioning for Hurler Syndrome
Successful hematopoietic cell transplantation (HCT) provides life-long disease-modifying therapy for children with Hurler syndrome (HS), most severe phenotype of α-L-iduronidase (IDUA) deficiency, as donor-derived leukocyte engraftment serves as a stable source of the deficient enzyme for in situ cross-correction of neighboring tissues and neurons [1-5]. Although recent outcomes suggest that overall survival (OS) and event-free survival (EFS) may approach 9 5% and 90%, respectively, in experienced centers [6], we have recently reported a striking evolution in the pattern of graft failure from delayed autologous recon...
Source: Biology of Blood and Marrow Transplantation - September 18, 2020 Category: Hematology Authors: Su Han Lum, Paul J. Orchard, Troy C. Lund, Weston P. Miller, Jaap Jan Boelens, Robert Wynn Source Type: research

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy
The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consistent of both transplant and non-transplant experts was invited to develop clinically relevant frequently asked questions covering disease- and HCT-related topics. A systematic literature review was conducted to generate core recommendations that were graded based on the quality and strength of underlying evidence based on the standardized criteria established by American Society of Transplantation and Cellu...
Source: Biology of Blood and Marrow Transplantation - September 18, 2020 Category: Hematology Authors: Bhagirathbhai Dholaria, Bipin N. Savani, Betty K. Hamilton, Betul Oran, Hien D. Liu, Martin S. Tallman, Stefan Octavian Ciurea, Noa G. Holtzman, Gordon L. Phillips II, Steven M. Devine, Gabriel Mannis, Michael R. Grunwald, Frederick Appelbaum, Cesar Rodri Source Type: research

Clinical and Neuroimaging Correlates of Post-Transplant Delirium
Hematopoietic stem cell transplantation (HCT) is one of the primary treatment modalities for individuals with leukemia, lymphoma, and other malignant and non-malignant conditions. Over one million HCTs have already been performed, with approximately 50,000 occurring annually [1,2]. With advancements in HCT therapies and an increasingly older population of candidates, the age of HCT recipients has continued to increase. Accordingly, there has been increasing interest in determining the prevalence and clinical factors associated with long-term cognitive impairment among HCT recipients, with a particular interest in the role ...
Source: Biology of Blood and Marrow Transplantation - September 18, 2020 Category: Hematology Authors: Patrick Smith, Jillian C. Thompson, Elena Perea, Brian Wasserman, Lauren Bohannon, Alessandro Racioppi, Taewoong Choi, Cristina Gasparetto, Mitchell E. Horwitz, Gwynn Long, Richard Lopez, David A. Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Nelso Source Type: research

Outcome after a cord blood transplantation using busulfan pharmacokinetic targeted myeloablative conditioning for Hurler syndrome
We report cord blood transplantation (CBT) outcomes of 97 children with Hurler syndrome (HS) after a busulfan pharmacokinetic targeted myeloablative conditioning regimens from 2004 to 2016. The median age at transplant was 10.8 months (range 0.23 – 63.2 months). The median follow-up for surviving patients was 4.2 years (range, 1.0 to 12.8 years). 5-year overall survival (OS) and engrafted survival (ES) were 88% and 79%. OS was 95% after Busulfan-Fludarabine-ATG, 90% after Busulfan-Cyclophosphamide-ATG and 74% after Busulfan-Cyclophosphamid e-Alemtuzumab (p=0.02). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 18, 2020 Category: Hematology Authors: Su Han Lum, Paul J Orchard, Troy C Lund, Weston P Miller, Jaap Jan Boelens, Robert Wynn Source Type: research

Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age
In 2018, it was estimated that around 9,000 patients received allogeneic hematopoietic cell transplantation (HCT) and 14,000 patients received autologous HCTs in the US.1 These numbers are expected to gradually increase at the rate of approximately 5% each year due to advances in HCT strategies, increased donor availability, improved pre- and post-transplantation care, and improvement in transplantation outcomes.2, 3 In response, the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program/Be The Match Registry have developed and sponsored a System Capacity Initiative (SCI). (Source: ...
Source: Biology of Blood and Marrow Transplantation - September 18, 2020 Category: Hematology Authors: Colin Flannelly, Bryan E-Xin Tan, Jian Liang Tan, Colin M. McHugh, Chandrika Sanapala, Tara Lagu, Jane L. Liesveld, Omar Aljitawi, Michael W. Becker, Jason H. Mendler, Heidi D. Klepin, Wendy Stock, Tanya M. Wildes, Andrew Artz, Navneet S. Majhail, Kah Poh Source Type: research

Paradoxical regulation of allogeneic bone marrow engraftment and immune privilege by mesenchymal cells and adenosine
A large body of evidence indicates that MSCs have immune suppressive potentials. MSC transfer showed therapeutic effects against various autoimmune disorders and graft-versus-host diseases in preclinical and clinical settings, leading to a growing interest in their clinical use.1 MSCs express various immune suppressive molecules, TGF-beta, IL-10, indoleamine 2,3-dioxygenase, and prostaglandin E2, inhibiting immune cells and expanding or generating Tregs.2 However, the role of endogenous MSCs in immune regulation in vivo remains largely unclear. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 18, 2020 Category: Hematology Authors: Miwako Kakiuchi, Yuichi Hirata, Simon C. Robson, Joji Fujisaki Source Type: research

Why hurry up and wait? Transplantation in Lower Risk MDS
Commentary: (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - September 18, 2020 Category: Hematology Authors: Tania Jain, Amy E. DeZern Source Type: research